Litigation over FDA approval of mifepristone presents “radically different versions” of the drug’s safety, says Dean Rebouche, and what the judges want to know about those differences will be important to both standing and questions about the FDA’s approval process.
Published on May 23, 2023
Abortion Pill Hearing Tees Up Showdown on Access, FDA Authority
